Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens.
Friday, April 26, 2013
COLD LASER THERAPY BASICS
Over 75 Trillion cells in a human body and they all need energy and electrons to communicate with each other. Laser light delivers the required electrons and energy directly to the cells, enhancing their ability to communicate with each other, absorb oxygen and nutrients and dispose of wastes and toxins. The laser delivers photons to the cells, and mitochondria, which they convert into ATP and use as energy for rebuilding and repairing tissues, tendons, ligaments, nerves and even bones.
Laser therapy is an exciting and relatively new field that can offer people a very safe and effective option to help with speeding up injury repair and reducing pain. provides a unique alternative to patients who are terrified of surgery or drugs, but still seek the powerful healing benefits.
A laser is defined as a device that produces intense radiation in the visible or near visible wavelengths. Laser light is unique in that it is close to one specific wavelength and propagates in-phase; meaning that all of the electro-magnetic waves oscillate together in an ordered and aligned way. Together, these conditions make up the term coherency. When the coherent light is columnated, it can travel vast distances with very little loss of power or scattering
Laser treatment used for healing is called “low-level laser” or “cold-laser” therapy. By definition, lasers used for cold-laser therapy range in power from 5 to 500 milliwatts (0.005 to 0.5 Watts). Lasers less than 5 milliwatts lack the power to induce a bio-stimulatory effect, while lasers greater than 500 milliwatts may cause excessive heating and burn the skin. Lasers used for surgery, however, range from 5 to 50 Watts
Approximately 3,000 clinical studies worldwide have attested to the beneficial and curative effects of therapeutic lasers.
Cold-laser therapy systems are available in several different wavelengths and colors…
A lot depends on what you are trying to heal. Each color reacts differently with the body.
Red lasers (660 nm) can penetrate more deeply, but are still generally used for surface conditions such as healing surface wounds such as bed-sores or diabetic ulcers,burns, acne, and hair restoration.
infrared lasers (905 nm) penetrate much deeper and are used to help heal muscle, ligament, and even bone.
The health benefits of cold laser therapy can be roughly divided into three categories:
1) Reduce inflammation
2) Reduce pain
3) Accelerate tissue repair
Laser Acupuncture
An increasing body of evidence suggests that laser treatments on specific acupuncture points can stimulate a similar effect as acupuncture needles.The use of laser acupuncture in the ears to help addiction and weight management cases
Dangers & Risks
One of the greatest risks of laser therapy is damage to the eyes. Cold-laser therapy treatments should always be conducted with proper safety glasses worn by both the patient and the practitioner. Other contraindications for laser treatment include:
• No treatment over suspect tumors or cancer cells
• No treatment over the thyroid
• No treatment over the fontanelle of infants
• No treatment if the patient is using photo-sensitive or immunosuppressant drugs.
These potential risks are a conservative precaution. Special exceptions are already being discovered including the use of laser-therapy to help with macular degeneration
Checklist to laser therapy
Adherence to the laser dosage recommendations from the world association for laser therapy is very important: the eight most important beam parameters are: wavelength, power, irradiation time, beam area at the skin or culture surface , pulse parameters, anatomical location, number of treatments, and interval between treatments.
The three commonly used dose parameters are time, energy, and energy density.
In addition coherence, application technique(contact, projection, scanning, pressure), beam profile, and spectral width may also be considered important.
Beam power often decreases as the device warms up and as the device ages
For further information please call 1-866-843-5273 or visit www.theralase.com
Friday, April 19, 2013
Theralase’s Innovative Anti-Cancer Technology Validated at Major International Conferences
Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc.
(TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology
has been accepted for presentation at two major international scientific
conferences. Acceptance at these conferences validates the significance of the technology
and its efficacy in the destruction of cancer cells in research performed by
Theralase's internationally acclaimed scientists.
The efficacy of the anti-cancer Photo Dynamic Compound technology will
be presented at LASER World of Photonics conference in Munich, Germany on May
15, 2013.
The effective destruction of bacteria using Theralase’s light activated
Photo Dynamic Compound technology will be presented at
Photonics North conference in Ottawa, Canada on June 3, 2013.
In further developments, Theralase’s Chief Scientific Officer, Dr.
Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers
in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level
Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal,
which publishes clinical and scientific studies concerned with the clinical and
scientific application of lasers and biophotonics in medicine for diagnostic
and therapeutic purposes. PLM recently featured the clinical success of Theralase’s
pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy
Applications for Osteoarthritis and Chronic Joint Pain.”
Roger Dumoulin-White, President and CEO of Theralase said, "I am
pleased that Theralase’s scientific and clinical research has been recognized
and acclaimed by two of the finest international scientific conferences and has
been published in a peer reviewed medical journal. Theralase is committed to
the early commercialization of its patented light activated Photo Dynamic
Compounds in the areas of anti-cancer and anti-bacterial applications to generate
substantial revenue increases for the Company. To accelerate this process, we
are actively looking to collaborate with strategic partners to further develop
our
technologies and increase shareholder value. Theralase’s strong PDC pipeline has
scientifically proven that our PDC technology is capable of consistently
producing cell kill levels of 100%, even at very low concentrations, across a
wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly
more effective in destroying cancer cells and bacteria than currently FDA
approved Photo Dynamic Compounds.”
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary
laser technology.
For further information please
visit www.theralase.com , regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com
Friday, April 12, 2013
TSX Venture Exchange Has Consented to the Extension of Warrants
THERALASE TECHNOLOGIES INC. ("TLT")
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: April 11, 2013
TSX Venture Tier 2 Company
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: April 11, 2013
TSX Venture Tier 2 Company
TSX Venture Exchange has consented to the extension in the expiry date of the following warrants:
Private Placement:
# of Warrants: Original Expiry Date of Warrants: New Expiry Date of Warrants: Exercise Price of Warrants: | 1,500,000 April 13, 2013 April 13, 2017 $0.38 | ||||||||||
These warrants were issued pursuant to a private placement of 3,000,000 shares with 1,500,000 share purchase warrants attached, which was accepted for filing by the Exchange effective April 16, 2012.
For further information please call 1-866-843-5273 or visit www.theralase.com
Monday, April 1, 2013
Theralase Applies to TSX Venture Exchange for Warrant Extension
Toronto, ON – March 28, 2013 - Theralase
Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that it has made
application to the TSX Venture Exchange for approval to extend the expiry date
of its outstanding common share purchase warrants.
Theralase has applied to have the expiry date of
the warrants amended from April 13, 2013 to April 13, 2017 for the 1,500,000 total
warrants issued on April 13, 2012. The exercise price of the warrants remains
unchanged at $0.38 per warrant, with the exception that the warrants will be
cancelled if they are not exercised within thirty (30) days from written notice
that the closing price of Theralase’s common
shares had been $0.75 or greater for 10 consecutive trading days.
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing proprietary Photo Dynamic Compounds (PDCs) that are able to target
and destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
For further information please visit www.theralase.com
, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-5273 ext. 225
Kristina Hachey
Chief Financial Officer
416-699-5273 ext. 224
Greg Bewsh
Director of Investor Relations
416-699-5273 ext. 258
Subscribe to:
Posts (Atom)